‘Immediate value’ISS supports Pfizer’s $179m takeover offer for ResApp
A UK-based proxy advisory firm has backed Pfizer’s new 20.8¢-a-share offer for ResApp Health, saying it represents a “significant premium” to the target’s share price before the bid was made.